Study guide
9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations
BCSCP Board Certified Sterile Compounding Pharmacist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview, USP Standards & CSP Categories
1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions
2 Chapter 2: Facilities, Engineering Controls & Cleaning
2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures
3 Chapter 3: Environmental Monitoring & Facility Certification
3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols
4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique
4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity
5 Chapter 5: Beyond-Use Dating, Storage & Container Rules
5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules
6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding
6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)
7 Chapter 7: Materials, Equipment & Compounding Workflow
7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs
8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility
8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics
9 Chapter 9: Therapeutics, Administration & Patient Monitoring
9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations
10 Chapter 10: Quality Management, Records & Personnel Competency
10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence
11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain
11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA
12 Chapter 12: Safety Management, Investigations, Recalls & Waste
12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management
9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations
Key Takeaways Explain This Topic AI
Intrathecal and epidural CSPs must be preservative-free, because preservatives such as benzyl alcohol, parabens and phenol can cause arachnoiditis and permanent neurologic injury.
Under USP <85>, the endotoxin threshold K K K is 0.2 EU/kg 0.2\,\text{EU/kg} 0.2 EU/kg for intrathecal use, compared with 5.0 EU/kg 5.0\,\text{EU/kg} 5.0 EU/kg for other parenteral routes, so intrathecal endotoxin limits are 25 times stricter.
Intraocular injections (for example bevacizumab, vancomycin or ceftazidime) must be preservative-free, close to physiological pH and tonicity, and within the USP <789> ophthalmic particulate limits to help prevent toxic anterior segment syndrome (TASS).
BCG for intravesical use is live attenuated Mycobacterium bovis. Its labeling requires biohazard handling, preparation in a biological safety cabinet, and preparation away from areas where parenteral drugs are made.
Last updated: September 2026
9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations
Important
Non-vascular routes of administration—including the central nervous system, intraocular structures, and the urinary bladder—bypass the human body's systemic buffering systems, reticuloendothelial clearance mechanisms, and cutaneous-mucosal barriers. Sterile compounds prepared for these anatomical sites demand uncompromising adherence to route-specific chemical purity, osmolarity, pH, particulate control, and preservative-free mandates to prevent permanent organ destruction or death.
Central Nervous System Routes: Intrathecal vs. Epidural Administration
Parenteral administration into the central nervous system (CNS) represents the highest risk tier in clinical sterile compounding. Understanding the anatomical and physiological distinctions between the epidural and intrathecal spaces is essential for clinical pharmacists.
Anatomical and Physiological Distinctions
Epidural Space : The epidural space is a potential space situated external to the dura mater and internal to the periosteum of the vertebral canal. It contains loose adipose connective tissue, extensive venous plexuses (Batson's plexus), lymphatics, and spinal nerve roots traversing the intervertebral foramina. Medications administered epidurally diffuse across the dural sleeve into the cerebrospinal fluid (CSF) or undergo systemic vascular uptake via the epidural venous plexus. Because of vascular uptake and systemic dilution, larger drug volumes and concentrations are typically required compared to the intrathecal route.
Intrathecal (Subarachnoid) Space : The subarachnoid space lies directly beneath the arachnoid mater and external to the pia mater, encasing the spinal cord and extending into the cerebral ventricles. It contains circulating cerebrospinal fluid. Total adult CSF volume is approximately 140 to 150 mL 140\text{ to }150\,\text{mL} 140 to 150 mL , with a turnover production rate of ∼ 500 mL/day \sim 500\,\text{mL/day} ∼ 500 mL/day ( 0.35 mL/min 0.35\,\text{mL/min} 0.35 mL/min ). The intrathecal space lacks adipose tissue, has virtually zero cellular bioburden, possesses low endogenous protein ( 15 − 45 mg/dL 15-45\,\text{mg/dL} 15 − 45 mg/dL ), and is devoid of humoral antibodies, complement proteins, or reticuloendothelial phagocytic cells. Drug solutions injected intrathecally come into immediate, unbuffered contact with vulnerable spinal cord parenchyma, unmyelinated nerve rootlets, and pial microvasculature.
Preservative-Free Mandates and Mechanisms of Neurotoxicity
Under no circumstances may a compounded sterile preparation containing antimicrobial preservatives, chemical stabilizers, or antioxidants be administered into the intrathecal or epidural space. Preserved commercial drug vials (e.g., bacteriostatic 0.9 % 0.9\% 0.9% sodium chloride, multi-dose local anesthetics, or preserved opioid formulations) are strictly contraindicated for neuraxial delivery.
Molecular Mechanisms of Preservative Neurotoxicity
Benzyl Alcohol : Commonly utilized as an antimicrobial preservative at concentrations of 0.9 % 0.9\% 0.9% in multi-dose injectables. When introduced into the neuraxial space, benzyl alcohol functions as a potent neurotoxin. It dissolves myelin sheath lipids, uncouples mitochondrial oxidative phosphorylation, and provokes direct axonal lysis. Intrathecal injection results in chemical arachnoiditis, myeloradiculopathy, irreversible paraplegia, and fatal toxic encephalopathy. Systemic accumulation in neonates precipitates the fatal "gasping syndrome."
Parabens (Methylparaben and Propylparaben) : Alkyl esters of p p p -hydroxybenzoic acid used widely for broad-spectrum antifungal and antibacterial preservation. In the intrathecal environment, parabens induce severe, progressive spinal adhesive arachnoiditis characterized by dense collagenous fibrosis of the leptomeninges, vascular obliteration, nerve root tethering, and intractable chronic neuropathic pain syndromes (cauda equina syndrome).
Phenol and Chlorobutanol : Phenol is a known neurolytic agent used intentionally in chemical neurolysis for intractable cancer pain. Inadvertent administration of phenol-preserved medications (e.g., preserved radiocontrast agents or multi-dose injectables) into the neuraxial space causes denaturing protein necrosis, non-selective destruction of sensory and motor tracts, and permanent flaccid paralysis.
Antioxidants and Excipients (Sulfites, Metabisulfites, EDTA) : Sodium metabisulfite and EDTA are frequently formulated into commercial epinephrine and opioid ampules. Metabisulfites cause direct neuronal vacuolation, axonal edema, and chemical meningitis. Compounding pharmacists must verify that all starting components (e.g., morphine, hydromorphone, bupivacaine, fentanyl) are labeled explicitly as "Preservative-Free" (PF) and antioxidant-free.
Bacterial Endotoxin Dynamics and Tolerances (USP <85>)
Bacterial endotoxins (lipopolysaccharides [LPS] from Gram-negative bacterial outer membranes) are potent pyrogenic toxins that survive standard thermal autoclaving and sterilizing 0.22 μ m 0.22\,\mu\text{m} 0.22 μ m filtration.
The Intrathecal Endotoxin Limit Equation
Per USP General Chapter <85> ( Bacterial Endotoxins Test ), the maximum permissible endotoxin limit ( L L L ) is calculated using the formula:
L = K M L = \frac{K}{M} L = M K
Where:
K K K is the threshold human pyrogenic dose of endotoxin per kilogram of body weight.
M M M is the maximum recommended human dose of the drug administered per kilogram within a single 1-hour period (assuming an average adult weight of 70 kg 70\,\text{kg} 70 kg if dosing is fixed).
The Intrathecal K K K -Value Disparity
Administration Route Threshold Pyrogenic Dose ( K K K ) Clinical Rationale
Systemic Parenteral (IV / IM) K = 5.0 EU/kg K = 5.0\,\text{EU/kg} K = 5.0 EU/kg Systemic endotoxins encounter hepatic Kupffer cells, circulating lipopolysaccharide-binding proteins (LBP), and splenic reticuloendothelial macrophages that neutralize and clear pyrogens.
Intrathecal (Subarachnoid) K = 0.2 EU/kg K = 0.2\,\text{EU/kg} K = 0.2 EU/kg The subarachnoid space has no hepatic clearance and lacks protective humoral binding proteins. Endotoxins bind directly to microglial CD14 and TLR4 receptors, triggering severe meningeal inflammation, pleocytosis, blood-brain barrier disruption, cerebral edema, intractable seizures, and fatal brain herniation.
Note
The endotoxin threshold for intrathecal preparations ( 0.2 EU/kg 0.2\,\text{EU/kg} 0.2 EU/kg ) is 25 times more stringent than that for systemic intravenous preparations ( 5.0 EU/kg 5.0\,\text{EU/kg} 5.0 EU/kg ). Intrathecal CSPs made from nonsterile components must meet the USP <797> endotoxin requirements: testing is required whenever the BUD requires sterility testing and for every Category 3 batch. The low K K K value makes a quantitative method, such as kinetic chromogenic or turbidimetric LAL, the practical choice.
Baricity and Tonicity Considerations in Intrathecal Compounding
Cerebrospinal Fluid Density : Normal human CSF has a specific gravity of 1.0063 to 1.0075 1.0063\text{ to }1.0075 1.0063 to 1.0075 at 37 ∘ C 37^\circ\text{C} 3 7 ∘ C (density ≈ 1.0003 − 1.0008 g/mL \approx 1.0003-1.0008\,\text{g/mL} ≈ 1.0003 − 1.0008 g/mL ).
Baricity refers to the ratio of the density of a local anesthetic solution to the density of human cerebrospinal fluid at body temperature:
Isobaric Solutions (Baricity ≈ 1.000 \approx 1.000 ≈ 1.000 ) : Formulated in 0.9 % 0.9\% 0.9% sodium chloride; remains localized at the anatomical segment of spinal injection, independent of patient gravitational positioning.
Hyperbaric Solutions (Baricity > 1.000 > 1.000 > 1.000 ) : Formulated by admixing the active drug with 5 % to 8 % 5\%\text{ to }8\% 5% to 8% dextrose injection. The higher density causes the drug to sink into gravitationally dependent curves of the spine (e.g., sacral or low thoracic pools) depending on whether the patient is placed in Trendelenburg or reverse Trendelenburg positioning.
Hypobaric Solutions (Baricity < 1.000 < 1.000 < 1.000 ) : Formulated by diluting the drug with sterile water for injection; density is lower than CSF, causing the drug bolus to float upward against gravity within the subarachnoid column.
Tonicity Requirements : Intrathecal solutions must remain strictly iso-osmotic (physiological target ∼ 280 − 300 mOsm/kg \sim 280-300\,\text{mOsm/kg} ∼ 280 − 300 mOsm/kg ). Infusion of hypotonic fluids causes rapid osmotic fluid shifts into unmyelinated neuronal axons, leading to intracellular edema and cellular lysis. Hypertonic solutions extract neuronal water, precipitating cellular desiccation, membrane rupture, and irreversible axonal shear injury.
Ophthalmic Sterile Preparations: Intraocular vs. Topical Routes
Sterile compounding for ocular therapies bifurcates into topical surface administrations and invasive intraocular injections, each carrying radically different compounding standards.
Comparison of Ophthalmic Administration Routes
Parameter Topical Ophthalmic Drops Intraocular / Intravitreal / Intracameral Injections
Anatomical Target Cornea, conjunctival sac, nasolacrimal canal Vitreous chamber (posterior cavity), anterior chamber (intracameral)
Representative Drugs Fortified tobramycin ( 14 mg/mL 14\,\text{mg/mL} 14 mg/mL ), fortified cefazolin ( 50 mg/mL 50\,\text{mg/mL} 50 mg/mL ), voriconazole 1 % 1\% 1% Bevacizumab ( 1.25 mg / 0.05 mL 1.25\,\text{mg}/0.05\,\text{mL} 1.25 mg /0.05 mL ), vancomycin ( 1 mg / 0.1 mL 1\,\text{mg}/0.1\,\text{mL} 1 mg /0.1 mL ), ceftazidime ( 2.25 mg / 0.1 mL 2.25\,\text{mg}/0.1\,\text{mL} 2.25 mg /0.1 mL ), dexamethasone
Preservative Allowance Permitted in multi-dose containers (e.g., benzalkonium chloride [BAK] 0.004 − 0.02 % 0.004-0.02\% 0.004 − 0.02% , polyquaternium-1, purite) ABSOLUTELY PRESERVATIVE-FREE . Zero preservatives permitted under any circumstance.
Target pH Near 7.4 7.4 7.4 is most comfortable; a wider range is tolerated because tears buffer and turn over As close to physiological (about 7.4 7.4 7.4 ) as the drug's stability allows
Target Osmolarity About 300 mOsm/kg 300\,\text{mOsm/kg} 300 mOsm/kg ; a wider range is tolerated on the surface Close to iso-osmotic (about 300 mOsm/kg 300\,\text{mOsm/kg} 300 mOsm/kg )
Particulate Standard USP <771> quality tests, which apply USP <789> to solutions USP <789> ( Particulate Matter in Ophthalmic Solutions ), with intraocular products held to the tightest practice
Volume Limit 25 − 50 μ L 25-50\,\mu\text{L} 25 − 50 μ L (one drop exceeds 30 μ L 30\,\mu\text{L} 30 μ L tear capacity) 0.05 to 0.10 mL 0.05\text{ to }0.10\,\text{mL} 0.05 to 0.10 mL maximum per injection to prevent intraocular pressure spikes
Pathogenesis of Toxic Anterior Segment Syndrome (TASS)
Toxic Anterior Segment Syndrome (TASS) is an acute, non-infectious, sterile inflammatory reaction of the anterior chamber occurring within 12 to 48 hours following intraocular surgery or injection. It is caused by chemical, particulate, or endotoxin contamination:
Preservative Cytotoxicity : Inadvertent introduction of benzalkonium chloride (BAK) into the anterior chamber causes instantaneous lysis of corneal endothelial cells. Because the corneal endothelium does not regenerate, massive cellular death results in permanent corneal stromal edema, bullous keratopathy, trabecular meshwork sclerosis, secondary glaucoma, and irreversible visual loss.
Endotoxin Contamination : Trace Gram-negative endotoxin residues in ophthalmic surgical fluids (such as intraocular irrigation solutions or intracameral cefuroxime/moxifloxacin) trigger an explosive local inflammatory cascade characterized by hypopyon, diffuse corneal haze, and fibrin exudation.
USP <789> Particulate Thresholds : Light obscuration particle limits for intraocular formulations are dramatically more stringent than intravenous limits: ≤ 50 particles/mL ≥ 10 μ m \le 50\text{ particles/mL} \ge 10\,\mu\text{m} ≤ 50 particles/mL ≥ 10 μ m , and ≤ 5 particles/mL ≥ 25 μ m \le 5\text{ particles/mL} \ge 25\,\mu\text{m} ≤ 5 particles/mL ≥ 25 μ m . Particulate matter inside the eye occludes trabecular meshwork outflow and triggers granulomatous uveitis.
Intravesical Instillations: Mitomycin C & BCG Containment
Intravesical chemotherapy involves the direct instillation of antineoplastic or immunotherapeutic agents into the bladder cavity via a urethral Foley catheter for the management of non-muscle-invasive bladder cancer (NMIBC).
Mitomycin C Formulation and Pharmacodynamics
Properties : Mitomycin C is an antitumor antibiotic and severe vesicant. Contact with exposed epithelium causes chemical cystitis, contact ulceration, and necrosis.
pH-Dependent Stability and Efficacy : Mitomycin C rapidly degrades in acidic aqueous media (half-life < 1 hour < 1\,\text{hour} < 1 hour at pH < 5.5 \text{pH} < 5.5 pH < 5.5 ). To optimize antineoplastic efficacy and minimize systemic urothelial reabsorption, patients undergo oral urine alkalization regimens (e.g., 1.3 g 1.3\,\text{g} 1.3 g oral sodium bicarbonate the night before and morning of instillation) to ensure urine pH > 7.0 \text{pH} > 7.0 pH > 7.0 .
Bacillus Calmette-Guérin (BCG) Biosafety and Handling Protocols
Bacillus Calmette-Guérin (BCG) is a freeze-dried suspension of live attenuated Mycobacterium bovis . Because it consists of viable mycobacteria, it presents severe compounding and occupational hazards. [Live Attenuated Mycobacterium bovis (BCG)]
- │
- ▼
Prepare as a biohazard:
- ├── Class II Biological Safety Cabinet (BSC) or CACI
- ├── Away from areas where parenteral drugs are prepared
- ├── Many facilities: externally vented BSC in a negative-pressure room
- │
- ▼
PROHIBITED ACTIONS:
- ├── NEVER compound in a positive-pressure LAFW
- ├── NEVER compound simultaneously with IV chemotherapy or TPN
- └── NEVER use standard alcohol rubs for spill decontamination
- │
- ▼
DECONTAMINATION STANDARD:
- └── EPA-Registered Tuberculocidal Disinfectant (Bleach / Accelerated H2O2)
- Crucial BCG Compounding Safeguards
Containment Standards : BCG labeling calls for handling it as biohazardous material, using Biosafety Level 2 (BSL-2) practices, and preparing it with aseptic technique in a biological safety cabinet . Many facilities also apply USP <800>-style containment, meaning an externally vented BSC or CACI in a negative-pressure room or C-SCA. Never use a laminar airflow workbench for BCG , because it blows air from the work zone toward the operator.
Separation from Parenteral Preparations : BCG labeling warns that nosocomial infections have followed parenteral drugs prepared in areas where BCG was reconstituted. Prepare BCG away from areas where parenteral drugs are compounded, and never in the same cabinet or at the same time. Contamination of an IV preparation with live Mycobacterium bovis can cause disseminated BCG infection.
Aerosol Prevention : Reconstitute gently, running diluent down the vial wall and following the labeling's mixing steps without vigorous shaking. Closed or vented reconstitution devices are commonly used to limit aerosols.
Spill Decontamination Protocol : Standard 70 % 70\% 70% sterile isopropyl alcohol (IPA) has poor mycobactericidal activity and is completely ineffective against dried mycobacteria. All BCG biohazard spills must be treated with an EPA-registered tuberculocidal disinfectant (e.g., sodium hypochlorite bleach solution or stabilized hydrogen peroxide with certified mycobactericidal activity) left wet for the full tuberculocidal contact time on the product label before wiping.